Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03487861

Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

Kidney Transplant Failure and Rejection Clinical Trial

Official title:
Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis

Clinical Trial Summary

The aim of this study is to verify the ability of transglutaminase type 2 to predict rejection or chronic allograft nephropathy of renal allograft. On the basis of biomolecular mechanisms aggravating chronic allograft nephropathy, we eventually expect to develop the remedy to prevent chronic allograft nephropathy after kidney transplantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03487861
Study type Observational
Source Asan Medical Center
Contact SUNG SHIN, MD, PhD
Phone 82-2-3010-3964
Email sshin@amc.seoul.kr
Status Recruiting
Phase
Start date August 29, 2017
Completion date December 31, 2020
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04057742 - AlloSure for the Monitoring of Antibody Mediated Processes After Kidney Transplantation
Recruiting NCT03465397 - Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients Phase 4
Completed NCT03437577 - Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients Phase 1/Phase 2
Not yet recruiting NCT05282966 - Assessment of QSant™ for Underlying Allograft Rejection
Recruiting NCT04388930 - The Microbiota in Kidney Donation and Transplantation
Completed NCT03611621 - A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Recruiting NCT05397821 - Pediatric Kidney Transplantation, Ureteroneocystostomy Techniques
Completed NCT04019353 - Cf-DNA Assay During Treatment of Acute Rejection
Recruiting NCT05806749 - Immunological Tolerance in Patients With Mismatched Kidney Transplants Phase 1
Recruiting NCT04936282 - Treatment of Early Borderline Lesions in Low Immunological Risk Kidney Transplant Patients (TRAINING) Phase 4
Enrolling by invitation NCT05285878 - Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation Phase 2
Recruiting NCT04526431 - Tacrolimus Pharmacokinetic Subpopulations
Active, not recruiting NCT03511560 - Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation Phase 4
Recruiting NCT03438773 - Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients Phase 1
Completed NCT05388955 - Risk Assessment Tool for Graft Survival in Pediatric Kidney Transplantation
Completed NCT04413916 - MiRNA in Kidney Transplantation: Association With Kidney Graft Function and Disease Process
Completed NCT03466775 - Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes N/A
Active, not recruiting NCT04733131 - Long-term Outcomes After Conversion to Belatacept
Active, not recruiting NCT03380962 - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Phase 1/Phase 2
Active, not recruiting NCT04154267 - Protocol Biopsies in High-risk Renal Transplant Recipients N/A